Aaron Gerds

Featured in: Favicon

nature.com Favicon

springer.com Favicon

jamanetwork.com Favicon

medscape.com Favicon

clevelandclinic.org Favicon

thelancet.com Favicon

healio.com Favicon

newsbreak.com Favicon

ascopubs.org Favicon

futuremedicine.com + 8 more

Articles

Dr Gerds on Unmet Needs in Low-Risk Myelofibrosis

Aug 6, 2024 | onclive.com | Aaron Gerds

CommentaryVideoAugust 6, 2024Author(s):Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.
Dr Gerds on Disease Progression Patterns in Low-Risk Myelofibrosis

Jul 10, 2024 | onclive.com | Aaron Gerds

CommentaryVideoJuly 10, 2024Author(s):Aaron Gerds, MD, discusses disease progression patterns from the MOST trial in patients with low-risk myelofibrosis. Aaron Gerds, MD, assistant professor, medicine, Hematology, and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, discusses findings from the prospective, observational MOST trial (NCT02953704), which collected disease progression data for patients with low- or intermediate-1–risk myelofibrosis.
What's Next? Trials and Therapeutics in Myelofibrosis

Jul 3, 2024 | medscape.com | Tania Jain |Aaron Gerds

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Tania Jain, MBBS: Hello, everyone, and welcome to this myelofibrosis podcast series. The topic for today is clinical trials and investigational therapeutics in myeloproliferative neoplasms (MPNs).
Dr Gerds on the Clinical Implications of Pelabresib Plus Ruxolitinib in Myelofibrosis

Jun 14, 2024 | onclive.com | Aaron Gerds

CommentaryVideoJune 14, 2024Author(s):Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis. Aaron Gerds, MD, assistant professor, medicine, Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, discusses the clinical implications of safety outcomes with of pelabresib (CPI-0610) plus ruxolitinib (Jakafi) in patients with JAK inhibitor–naive myelofibrosis.
Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior-Naive Myelofibrosis

May 31, 2024 | onclive.com | Aaron Gerds

Aaron Gerds, MD, assistant professor in medicine, Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, discusses updated efficacy and safety results from the phase 3 MANIFEST-2 trial (NCT04603495) of pelabresib (CPI-0610) plusruxolitinib (Jakafi) in patients with JAK inhibitor–naive myelofibrosis.
Dr Gerds on the Importance of Evaluating Selinexor in JAK Inhibitor-Naive Myelofibrosis

Jan 4, 2024 | onclive.com | Aaron Gerds

Aaron Gerds, MD, assistant professor in medicine, Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, discusses the importance of evaluating the efficacy and safety of selinexor (Xpovio) in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial (NCT04562389). Selinexor, a selective inhibitor of nuclear export, is an active agent that has already been studied in the treatment of various hematologic malignancies, Gerds begins.
Monitoring Patients on Treatment for MF

Dec 22, 2023 | targetedonc.com | Aaron Gerds

Aaron Gerds, MD, MS, explains that myelofibrosis patients on JAK inhibitors need regular monitoring of blood counts, liver enzymes, and cardiac events to check for reactivation.
Future of Myelofibrosis Treatments

Dec 22, 2023 | targetedonc.com | Aaron Gerds

Future of Myelofibrosis TreatmentsAaron Gerds, MD, MS, shares hopes that combination therapies now in trials, along with other novel approaches further down the pipeline like monoclonal antibodies, vaccines, and cellular therapies will likely radically advance treatment over the next 5 to 10 years.
Safety of Available JAK Inhibitors for Treatment of MF

Dec 22, 2023 | targetedonc.com | Aaron Gerds

Safety of Available JAK Inhibitors for Treatment of MFAaron Gerds, MD, MS, reviews key safety concerns seen with JAK inhibitors for myelofibrosis treatment.
Approaches to Switching Therapies for Patients With MF

Dec 22, 2023 | targetedonc.com | Aaron Gerds

Approaches to Switching Therapies for Patients With MFWhen switching JAK inhibitors for myelofibrosis, Aaron Gerds, MD, MS, advises stopping ruxolitinib and starting the new JAK inhibitor the next day due to its short half-life, though tapering ruxolitinib over 1 week is recommended for patients on higher doses to avoid rebound symptoms; pacritinib and fedratinib have longer half-lives so a 1-week washout can be considered.